Related Experiment Video

Updated: Apr 15, 2026

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.9K

Intratumoral Heterogeneity: From Diversity Comes Resistance

Ariel Pribluda1, Cecile C de la Cruz1, Erica L Jackson2

  • 1Discovery Oncology, Genentech, Inc., South San Francisco, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 4, 2015
PubMed

Insights

Tumors have diverse cancer cell types. This intratumoral heterogeneity drives tumor growth and resistance to therapies, potentially causing treatment failure and relapse.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Medicine

Background:

  • Tumors are composed of functionally distinct cancer cell subpopulations.
  • These differences arise from variations in receptor activity, differentiation, metabolism, and epigenetics.
  • Intratumoral heterogeneity can foster cell interdependence, crucial for sustained tumor growth.

Purpose of the Study:

  • To explore the implications of intratumoral heterogeneity in cancer.
  • To understand how cellular diversity contributes to tumor progression and therapeutic resistance.

Main Methods:

  • Analysis of cancer cell functional states.
  • Investigation of cell-cell interactions within tumors.
  • Review of clinical data on treatment responses.

Main Results:

  • Functional differences among cancer cells are driven by diverse molecular states.
  • Cellular interdependence within tumors is a consequence of intratumoral heterogeneity.
  • Subpopulation variability significantly impacts responses to chemotherapy and targeted agents.

Conclusions:

  • Intratumoral heterogeneity is a key factor in tumor growth and survival.
  • Understanding cellular diversity is critical for overcoming therapeutic resistance.
  • Heterogeneity may explain incomplete treatment responses, acquired resistance, and clinical relapse.

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K